Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858430 | 0.82 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2C9TDP1HPGD | |
| SCHEMBL2858432 | 0.82 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2C9TDP1HPGD | |
| SCHEMBL6176844 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2C9TDP1HPGD | |
| SCHEMBL30559660 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2C9TDP1HPGD | |
| SCHEMBL1611986 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2C9TDP1HPGD | |
| SCHEMBL146603 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2C9TDP1HPGD | |
| SCHEMBL182660 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2C9TDP1HPGD | |
| SCHEMBL367154 | 0.78 | TDP1 (0.47) | CYP1A2CYP2C19CYP2C9TDP1HPGD | |
| SCHEMBL28689862 | 0.78 | TDP1 (0.47) | CYP1A2CYP2C19CYP2C9TDP1HPGD | |
| SCHEMBL27869707 | 0.77 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP2C9TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100605-A1 | Methods of treating cancer with angiogenesis inhibitors | GRUPP STEPHAN A (US) | 2003-05-29 | — | — | US | disclosed |
| US-6017954-A | ANGIOGENESIS INHIBITORS FOR TREATING AND PREVENTING ANGIOGENESIS-DEPENDENT TUMORS, ESPECIALLY KAPOSI'S SARCOMA, BREAST CANCER, COLON CANCER | CHILDREN'S MEDICAL CENTER CORP. (US) | 2000-01-25 | — | — | US | disclosed |
| US-5698586-A | ADMINISTERING AN O-SUBSTITUTED FUMAGILLOL | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0359036-B1 | Fumagillol derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-03-26 | — | — | EP | disclosed |
| EP-0682020-A1 | Fumagillol derivatives useful as angiogenesis inhibitors | Takeda Chemical Industries, Ltd. (JP) | 1995-11-15 | — | — | EP | disclosed |
| EP-0357061-B1 | Angiogenesis inhibitory agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5290807-A | Antiinflammatory agents | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-03-01 | — | — | US | disclosed |
| US-5180738-A | Angiogenesis Inhibitors | TAKEDA CHEMICAL INDUSTRIES (JP) | 1993-01-19 | — | — | US | disclosed |
| US-5166172-A | Angiogenesis inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| US-5164410-A | Fumagillol derivatives and pharmaceutical compositions thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-17 | — | — | US | disclosed |
| US-5047397-A | Natriuretics, diuretics, vasodilators | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0410989-A4 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | — | 1991-06-05 | — | — | EP | disclosed |
| EP-0410989-A1 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1991-02-06 | — | — | EP | disclosed |
| US-4935492-A | Cyclic analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0359036-A1 | Fumagillol derivatives | Takeda Chemical Industries, Ltd. (JP) | 1990-03-21 | — | — | EP | disclosed |
| EP-0357061-A1 | Angiogenesis inhibitory agent | Takeda Chemical Industries, Ltd. (JP) | 1990-03-07 | — | — | EP | disclosed |
| WO-1989009611-A1 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-10-19 | — | — | WO | disclosed |
| EP-0323740-A2 | Linear analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1989-07-12 | — | — | EP | disclosed |
| WO-1989005654-A1 | LINEAR ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100605-A1 | Methods of treating cancer with angiogenesis inhibitors | VEGFA, FLT4, HIF1AN | CYP1A2 4791/4885CYP2C19 4873/4885CYP2C9 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.